Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined th...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Hightower, Kendra E., Wang, Ruolan, DeAnda, Felix, Johns, Brian A., Weaver, Kurt, Shen, Yingnian, Tomberlin, Ginger H., Carter, H. Luke, Broderick, Timothy, Sigethy, Scott, Seki, Takahiro, Kobayashi, Masanori, Underwood, Mark R.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2011
Teme:
Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3187001/
https://ncbi.nlm.nih.gov/pubmed/21807982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00157-11
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items